Immunoregulatory protein-siRNA complex having anticancer activity
US11246939B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 17, 2019 |
| Grant date | Feb 15, 2022 |
| Priority date | — |
| Expiry date | Sep 17, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3513
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.